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ABSTRACT 
Objective. There is scant evidence to guide physicians in 
the choice of one therapeutic agent or combination over 
another to treat children and adolescents with enthesites-re-
lated arthritis (ERA). Clinicians not only need to know 
about the efficacy of disease-modifying anti-rheumatic 
drugs (DMARDs) and biologic as stand-alone therapy ver-
sus placebo, but also how they work in combination and in 
comparison  to one another.  
The main objective of the study is to characterized the effec-
tive of biologic exposure in children with ERA over the first 
year after diagnosis. 
Methods. We conduced a multicenter retrospective study of 
children diagnosed with ERA followed in several hospital: 
Children’s Hospital of Philadelphia, Alabama Children’s 
Hospital, Cincinnati Children’s Hospital, Texas Scottish 
Rite Hospital for Children and Meyer Children’s Hospital. 
We estimated the effect of biologic therapy on clinical pa-
rameters (active joint count, tender enthesis count, develo-
pment of sacroiliitis), physician disease activity assessment, 
and patient-reported pain and global assessment of disease 
activity over the first year after diagnosis using a weighted 
repeated measures approach.  
Results. During the study period, 218 newly diagnosed 
ERA patients had a total of 968 clinic visits the first year di-
sease onset. 35 (16.1%), 70 (32.1%) and 56 (25.7%) were 
treated with biologic, DMARD monotherapy, or both, re-
spectively during the first year after diagnosis. Over the first 
year after disease onset, use of a biologic was significantly 
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associated with less pain (p=0.03) and improved disease ac-
tivity as measured by the JADAS-3 (p=0.02). Use of a bio-
logic, versus no biologic, was associated with a significant 
greater negative slope (or faster change over the time) in 
tender entheses count (p<0.01). 
Conclusion. During the first year after diagnosis, biologic 
exposure was associated with benefits for several clinically 
meaningful outcomes in children with enthesites-related ar-
thritis.  
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INTRODUCTION 
Juvenile idiopathic arthritis (JIA) is the most common 
rheumatologic chronic condition in childhood. Enthesitis-
related arthritis (ERA) is a JIA category that accounts for 
10-20% of JIA [1-3], which preferentially affects boys, most 
frequently in the preadolescent and adolescent age group.  
ERA is defined as arthritis and enthesitis of at least six 
weeks duration in a child younger than 16 years, or arthritis 
or enthesitis plus two of the following criteria: sacroiliac 
tenderness or inflammatory back pain, HLA-B27 positivity, 
onset of arthritis in a male older than six years, and family 
history of HLA-B27 associated disease [4]. The presence of 
HLA-B27 is often associated with this subset of JIA, even if 
it is not required for diagnosis.  
The ERA category describes a clinically heterogeneous 
group of children including some that have predominantly 
enthesitis, enthesitis and arthritis, juvenile ankylosing spon-
dylitis, or inflammatory bowel disease associated arthropa-
thy. Enthesitis is defined as inflammation of an enthesis, 
which is a site where tendons, ligaments, or joint capsules 
attach to bone. Enthesitis is common in ERA and may not 
parallel the activity of arthritis.  
Extra-articular manifestations (gastrointestinal, ocular, mu-
cosal, and cutaneous) occur in variable portion of patients. 
ERA causes comparable morbidities to the other JIA catego-
ries including articular destruction, functional decline, and 
uveitis. Additionally, this type of JIA may cause dactylitis, 
spinal involvement, and a subset of children will progress to 
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ankylosing spondylitis as adults, which is characterized by 
spinal and back pain, stiffness, and eventual fusion of verte-
brae [5, 6]. Unlike adult ankylosis spondylitis, inflammatory 
back pain is rarely present at onset, even though sacroiliac 
and spinal involvement may occur in up to two-thirds of pa-
tients during the first 10 years of disease [7]. Observational 
studies suggest that ongoing disease activity for more than 
five years predicts disability and the disease remission oc-
curs in less than 20% of children with ERA five years after 
diagnosis [8]. 
Up to now, there is scant evidence to guide physicians in the 
choice of one therapeutic agent or combination over ano-
ther. Clinicians not only need to know about the efficacy of 
disease-modifying anti-rheumatic drugs (DMARDs) and 
biologic as stand-alone therapy versus placebo, but also how 
they work in combination and comparison to one another. 
Moreover, the comparative effectiveness and safety of diffe-
rent treatment algorithms for children with ERA remain un-
clear and without consensus.  
Treatment regimens for ERA include monotherapy or com-
bination therapy with non steroidal anti-inflammatory drugs 
(NSAIDs), DMARDs such as methotrexate, sulfasalazine, 
and leflunomide, or biologic agent such as etanercept, ada-
limumab, and infliximab.  
There are only two randomized clinical trials focused on 
children with ERA [9, 10]; the majority of trials include 
ERA as one of several JIA categories. Both of the published 
ERA trials included only children with prevalent disease 
who had failure at least one NSAID and one DMARD and 
who had at least 3 active joints [9,10]. In both trials treat-
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ment with biologic resulted in sustained clinical improve-
ment. In another study, which included a subset of children 
with prevalent ERA disease (average disease duration 2 
years) and at least 2 active joints, etanercept resulted in im-
provement in the pedi-ACR response criteria, tender enthe-
ses count, back pain, and back mobility [11]. There are no 
published trials of induction therapy for children with ERA. 
The choice of induction treatment algorithms for children 
with this type of JIA, according to the American College of 
Rheumatology (ACR) treatment recommendations, are ba-
sed solely on the number of active joints [12]. Using this al-
gorithms the earliest a child with ERA might be treated with 
a biologic is after 3 months of therapy with DMARD. The 
comparative efficacy of DMARD versus biologic therapy in 
children with the new onset of ERA remains unclear.  
In this retrospective study we used a repeated measures de-
sign to evaluate the impact of biologic therapy on relevant 
clinical and patient-reported outcomes in children from 5 
centers with new-onset ERA. Treatments were based upon 
provider and family preferences. The use of a weighted ap-
proach enable assessment of biologic effect in this cohort 
with balance in time-invariant cofounders.  
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METHODS 
We performed a multicenter retrospective study in children 
who fulfilled the International League of Associations for 
Rheumatology (ILAR) criteria for ERA [4] and had at least 
6 months of documented follow-up at a rheumatology cli-
nic, at one of the following academic tertiary care referral 
centers: Children’s Hospital of Philadelphia (CHOP, Phila-
delphia, PA), Children’s of Alabama (Birmingham, Alaba-
ma), Cincinnati Children’s Hospital Medical Center (Cin-
cinnati, Ohio), Texas Scottish Rite Hospital for Children 
(Dallas, TX), and Meyer Children’s Hospital (Florence, Ita-
ly). All children had to fulfill ILAR criteria for ERA within 
6 months of disease onset. Children who met ERA criteria 
but had a first-degree relative with psoriasis were not exclu-
ded (n=7). Children and adolescente who transferred care 
from another institution and/or who were already receiving 
therapy at the time of initial evaluation were excluded.  
Each institution queried their respective clinical database for 
all children diagnosed with ERA in the outpatient health re-
cord at the initial or subsequent follow-up visit. The range 
of diagnosis dates included from each institution varied de-
pending upon availability of searchable medical records and 
are as: CHOP 2001-2012, Children’s of Alabama 
2007-2012, Cincinnati Children’s Hospital Medical Center 
2007-2012, Texas Scottish Rite Hospital for Children 1993-
2011, and Meyer Children’s Hospital 1995-2012. 
Inclusion criteria were: males or females ages 2 to 18 years 
old, evaluated at a study site during the study period, affec-
 8
ted by ERA according to ILAR criteria. Exclusion criteria 
were incomplete or missing data. All inclusion and exclu-
sion criteria were verified by the coordinating center using 
the JIA Calculator [13]. The JIA Calculator is a web-based 
tool to help algorithmically classify children with according 
to ILAR criteria [4]; 39 children were excluded after this 
process.  
The study was approved by the committees for the protec-
tion of human subjects at each of the participating institu-
tions. CHOP served as the coordinating center.  
Clinical characteristics 
Baseline visit was defined as the first rheumatology visit at 
which the child presented with clinical signs of ERA, such 
as enthesitis, arthritis, acute uveitis or inflammatory back 
pain. The following clinical data were abstracted from the 
medical record: demographic (sex, age, race, disease onset 
and disease duration), personal and family history of HLA-
B27 associated disease, clinical features (including develo-
pment of new sacroiliitis demonstrated on MRI), laboratory 
data (including ANA, HLA-B27, rheumatoid factor, anti-ci-
trullinated cyclic peptide, inflammatory markers), patient 
reported outcomes (disease activity assessment and pain), 
past and current medications. Disease activity at each visit 
was measured using physician disease activity assessment 
(range 0-10), the Juvenile SpondyloArthritis Disease Activi-
ty Index (JSpA DAI) (Table 1) [14], and the juvenile Arthri-
tis Disease Activity Score 3 (JADAS-3) [15]. The JSpA DAI 
is a validated composite measure developed specifically for 
children with juvenile spondyloarthritis that include 8 items: 
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active joint count, active entheses count, pain, ERS or CRP 
related to juvenile spondyloarthropathy activity, morning 
stiffness, clinical sacroilitis, back mobility. The score has a 
range from 0-8 that is obtained by summing the total for 
each item (maximum total for item=1). A higher scores in-
dicating a more disease activity [14]. 
The JADAS-3 is also a validated composite disease measure 
but it was specifically developed for all juvenile idiopathic 
arthritis category, and range from 0 (inactive disease) to 30 
(highest disease activity). This index is very useful in the 
clinical practice also because ESR is excluded from the item 
[15]. 
All data were entered into a customized database (called 
REDCap) managed by the CHOP. 
Statistical analysis 
In order to assess which clinical factors impact the decision 
to treat with a biologic we fit a multilevel mixed-effects lo-
gistic regression model with adjustment for clustering by 
patient and site. Covariates tested included: study day, age, 
sex, race, HLA-B27 status, glucocorticoid use and presence 
of hip arthritis, wrist arthritis, sacroilitiis, or uveitis. The 
model include all visit up to and including the first visit 
where a biologic was prescribed. We used locally weighted 
scatterplot smoothing (Lowess) to also visually evaluate 
how disease activity scores influenced the probability of 
being prescribed biologic medication. JSpA DA scores were 
plotted against whether or not a biologic was prescribed at 
the visit or not.  
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Marginal structural models (MSMs) were used to estimate 
the casual effect of biologic treatment [16]. This approach 
appropriately controls for time-decedent confounders affec-
ted by prior treatment through creating a pseudo-population 
in which treatment is unconfounded by subject-specific cha-
racteristics and no censoring occurs. The model is fitted in a 
two-stage process. First at each time point each subject’s 
probability of having their own treatment history and proba-
bility of being censored are derived as inverse-probability-
of-treatment weight (IPTWs) and inverse-probability-of-
censoring weight (IPCWs) respectively by pooled logistic 
regression. Next, the association between the treatment and 
outcome measured repeatedly is evaluated in a generalized 
estimating equation (GEE) model that is weighted using the 
IPTWs and IPCWs. Because of the weighting, the regres-
sion now takes places in the pseudo-population which as-
sumes no unmeasured confounding and censoring, and re-
sults in unbiased estimate of the treatment effect and out-
come. 
The development of the weights at each visit took into ac-
count demographics, time-invarant clinical variables inclu-
ding HLA-B27 positivity and year of diagnosis (dichotomi-
zed as before or after biologic approval for JIA by FDA), 
and time-varying clinical variables that might influence the 
use of biologic therapy, including glucocorticoid use, hip 
arthritis, wrist arthritis, sacroiliitis (demonstrated on ima-
ging), and acute anterior uveitis. Stability of the weights 
was assessed graphically at intervals of 60 study days. 
For the weighted GEE model, the primary outcome was the 
active joint count measured over the time. Secondary out-
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comes assessed included repeated measures of the tender 
entheses count, physician disease activity assessment, JSpA 
DAI, JADAS-3, patient assessment of disease activity, pa-
tient-reported pain, and development of sacroiliitis after 
diagnosis. A negative binomial distribution with log link 
was assumed to account for the over dispersion for active 
joint count and tender entheses count due to the number of 
zero counts. Normal distribution with identity link was used 
for the remainder of outcomes. The models for active joint 
count, physician disease activity assessment, JSpA DAI, 
JADAS-3, patient assessment of disease activity, and pa-
tient-reported pain included the following variables: biolo-
gic use, DMARD use, age, sex, study day, an interaction 
between study day and biologic use, and accounted for clu-
stering within site and weighted inverse probability of bio-
logic use (from step 1). The model for tender entheses count 
included the same variables with the addition of HLA-B27 
since our prior work has shown HLA-B27 status is a predic-
tor of tender entheses course.  
Data regarding development of new sacroiliitis was only 
available for 4 sites. The association of development of new 
sacroiliitis and biologic use at these 4 sites was tested using 
chi-square analysis. 
All analyses were run using Stata (StataCorp. 2015, Stata 
Statistical Software: Release 14. College Station, TX: Sta-
taCorp LP) or SAS software 9.3 (Copyright ? 2011, SAS 
Institude Inc., Cary, NC, USA). 
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RESULTS 
Subjects 
During the study period, 218 newly diagnosed ERA patients 
had a total of 968 outpatient visits the first year after disease 
onset. The median age for the records was 11.6 years. De-
mographics and clinical characteristics of the cohort are 
shown in Table 2.  
176 (80.7%), 22 (10.1%), 20 (9.2%) of children had arthritis 
and enthesitis, arthritis plus 2 or more additional ILAR cri-
teria, or enthesitis plus 2 or more additional ILAR criteria, 
respectively. The population was predominantly male and 
58% were HLA-B27 positive. 
Sixty-four (32%) had a polyarticular course. The treating 
provider performed imaging for sacroilitiis based on clinical 
suspicion. Twenty-one children (14%) had evidence of sa-
croiliitis on imaging at diagnosis and an additional 14 (11%) 
developed sacroiliitis over the first year of follow-up. Of the 
35 with sacroiliitis at some point during the first year, 21 
(60%) were HLA-B27 positive. 
Medication use 
33 (15.1%), 73 (33.5%), and 52 (23.9%) were treated with 
biologic monotherapy, DMARD monotherapy, or simulta-
neous DMARD and biologic therapy, respectively during 
the first year after disease onset. Two patients (1%) were 
switched from a DMARD to a biologic without any overlap 
in the medications. Adalimumab, etanercept, and infliximab 
accounted for 17 (19.5%), 63 (72.4%), and 7 (8.1%) of bio-
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logic use, respectively. Seventy-nine (91%) of children who 
started a biologic remained on biologic therapy for the dura-
tion of follow-up. Nine (10%) biologic users switched bio-
logic during the course therapy. The median time to biologic 
switch was 155 days (IQR: 62, 163). Of the 8 children who 
stopped the biologic before the end of follow-up, 1 had pre-
viously tried a different biologic.  
We evaluated whether the severity of disease and certain di-
sease manifestations were associated with the probability to 
prescribe a biologic. In a multilevel mixed-effects logistic 
analysis, the presence of wrist, hip, or sacroiliac arthritis 
were all associated with increased odds of biologic exposure 
(Table 3). This type of bias often results in the exposure 
being errantly associated with poorer outcomes [17]. As di-
sease activity increased for JSpA DAI, the probability of re-
ceiving biologic also increased, a finding consistent with 
confounding by indication (Figure 1). 
One hundred (78.7%), 26 (20.5%), and 1 (0.8%) of the pa-
tient were treated with methotrexate, sulfasalazine, and le-
flunomide, respectively. Of the 127 children treated with 
any DMARD, 27 (20%) discontinued DMARD use before 
the end of follow-up. One hundred and eighty-nine (86.7%) 
and 58 (26.6%) were treated with continuous NSAIDs or 
systemic glucocorticoids, respectively. Sixty-two (28.4%) 
received at lest 1 joint injection. The median number of 
joint injections in patient who underwent the procedure was 
1 (IQR: 1, 2). 
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Outcomes  
Results of the weighted GEE model, which adjusted for the 
confounding and censoring through weighting, are shown in 
Table 4. Over the first year after disease onset, patients who 
received a biologic were more likely to have a lower JA-
DAS-3 (p=0.02) and less pain (p=0.03), when holding a co-
variates constant. Use of a biologic was associated with im-
provement, albeit statistically insignificant, in all other cli-
nical, disease activity, and patient assessment. Use of a 
DMARD was associated with significantly lower tender en-
theses count (p=0.01) and physician disease activity as-
sessment (p=0.03). DMARD use, similar to biologic use, 
was associated with improvement, albeit statistically insi-
gnificant in all other outcomes; the magnitude of the estima-
te, however, was dampened for all outcomes in comparison 
to the estimate for biologic use.  
Interestingly, female sex was associated with significantly 
higher tender enthesis count (p=0.03), higher JADAS-3 (p 
<0.01), higher patient disease activity assessment (p <0.01), 
and more pain (p <0.01). 
Fourteen children were diagnosed with sacroiliitis by ima-
ging over the course of follow-up. Twelve (86%) of these 
children were not being treated with a biologic at the time of 
sacroiliitis diagnosis (p <0.01). Three of these children were 
subsequently started on biologic therapy. When stratified by 
HLA-B27 status, lack of biologic exposure remained signi-
ficantly associated with development of new sacroiliitis 
(both p <0.01).  
Use of a biologic, versus no biologic, was significantly as-
sociated with a faster change over the time in tender enthe-
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ses count (p <0.01). The change over time in all outcomes in 
children treated with biologic monotherapy, biologic plus 
DMARD, DMARD monotherapy, and supportive care only 
(NSAIDs, glucocorticoids, intra-articular joint injections) 
are shown in Figure 2 and 3. For all outcomes the rate of 
change was fastest for those children treated with both bio-
logic and DMARD, followed by biologic status; those pa-
tients who were HLA-B27 negative started with significan-
tly higher baseline tender entheses count than those who 
were HLA-B27 positive.  
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DISCUSSION 
According to the ACR recommendations for the treatment 
of JIA [12], initiation of TNF α inhibitor is recommended 
more readily for patients with active sacroiliac arthritis than 
for patients without this joint affected. The beginning of 
biologic treatment was recommended for subjects with acti-
ve sacroiliac arthritis who have received an adequate trial of 
NSAIDs and have high disease activity and features of poor 
prognosis (Table 5). Moreover, anti-TNF is also recommen-
ded for patients who have received 3 months of methotrexa-
te and have high disease activity, irrespective of prognostic 
factors, or moderate disease activity with features of poor 
prognosis, or 6 months of methotrexate and moderate disea-
se activity without features of poor prognosis. Also, initia-
tion of a TNF-α inhibitor has been supported for patients 
who have received 3 months of sulfasalazine and have mo-
derate or high disease activity, or 6 months of sulfasalazine 
and low disease activity with features of poor prognosis [12, 
18, 19]. 
In our multicenter observational study we reported the effect 
of biologic exposure in children with newly diagnosed ERA 
over the first year after disease onset. Our data suggest that 
biologic treatment is associated with statistically significant 
improvement in disease activity and pain over the first year 
after diagnosis. Furthermore, the direction of our estimates 
was consistent across all outcomes measures. DMARD the-
rapy, as expected, also improved outcomes measures. The 
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magnitude of estimated effect, however, was uniformly 
greater in children treated with a biologic versus a DMARD.  
However, in our study design we haven’t assessed if there 
was a difference statistically significant between a particular 
type of DMARDs (i.e. methotrexate or sulfasalazine) or a 
particular type of biologic (i.e. etanercept or adalimumab) 
into determinate an improvement of disease. Further studies 
are needed to investigate this aspect.  
Moreover, several findings warrant additional discussion. 
First, as with any observational of therapeutic intervention, 
the possibility of confounding-by-indication bias must be 
considered. This bias arises when children with more severe 
disease manifestation are more likely to receive the exposu-
re of interest and experience poorer outcomes. In this study, 
we did find evidence that children with higher disease acti-
vity and more severe disease manifestations (cervical, axial, 
ocular inflammation) were more likely to receive biologic 
therapy within first 3 months, as demonstrated in Table 3 
and Figure 1. Our weighted GEE model, which adjusted for 
the confounding and censoring through weighting, likely 
minimized but did not remove this bias. Since we demon-
strated that the children who received biologics had a grea-
ter magnitude of beneficial effect than children who receive 
DMARDs, and that the slope of change was greatest in chil-
dren who received a biologic with or without a DMARD, 
the possibility exists that biologics have an even greater po-
sitive effect on clinical and patient-reported outcomes than 
we were able to demonstrate.  
Second, this study was not designed to systematically eva-
luate for the presence of axial arthritis. Imaging for suspi-
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cion of axial disease was done as per the treating physician. 
Interestingly, 11% of children had axial involvement reco-
gnized on MRI evaluation at some point during the first year 
after disease onset. Of these, 86% were not being treated 
with biologic. It is unclear if early biologic use was “protec-
tive” against development of axial arthritis in those treated 
with biologic or if early use of a biologic suppressed axial 
disease symptoms and therefore the need for subsequent 
imaging. Prior studies have shown that in children with 
newly diagnosed JSpA and MRI evidence of sacroiliitis 
(both active and chronic lesion), up 2/3 may not have symp-
toms. Without the use of universal screening to detect sub-
clinical sacroiliitis the true efficacy of biologics for this di-
sease manifestation will remain unknown. The role of early 
biologic use in JSpA remains unclear and has not been sy-
stematically evaluated.  
In summary, this study supports the effectiveness of biolo-
gics within the first year after disease onset in everyday cli-
nical practice. Children treated with biologics had impro-
vement in all clinical features and patient-reported outco-
mes, albeit some statistically insignificant. Next steps 
should include efficacy trials of early biologic use versus 
traditional DMARDs in regards to time to inactive disease, 
risk treatment of sacroiliitis, patient-reported outcomes, and 
cost saving. 
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Table 1. JSpA DAI items (N=610 visits) 
 
Legend. JSpA DAI Items.*Score is obtained by summing 
the total for each item (maximum total per item=1).  Range 
of possible scores is 0 to 8, with higher scores indicating 
more disease activity. SD= Standard deviation 
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from: Development and retrospective validation of the juve-
nile spondyloarthritis disease activity index.  
Authors: Weiss PF, Colberti RA, Xiao R, Feudtner C, Beu-
kelman T, DeWitt EM, Pagnini I, Wright TB, Wallace CA.  
Arthritis Care Research (Hoboken). 2014;66(12):1775-82.  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Table 2. Patient Characteristics at Diagnosis  
N=218
Demographics
Age, Median (IQR) 11.6 (9.6, 
13.8)
Sex (male), N (%) 157 (72)
Race, Caucasian, N (%) 182 (83.5)
ILAR ERA criteria, N (%)
Arthritis 187 (85.8)
Enthesitis 145 (66.5)
Sacroiliac joint tenderness and/or inflammatory 
spinal pain
70 (32.1)
Acute, symptomatic uveitis 14 (6.5)
Onset of arthritis in a male >6 years 132 (60.6)
Family history of HLA-B27+ associated disease in 
a first degree relative
36 (16.7)
Clinical Features and Patient Reported Outcomes at 
Diagnosis, Median (IQR)
Active Joint Count 2 (1, 4)
Tender Enthesis Count 2 (0, 3)
Physician disease activity (VAS 0-10) 2.4 (2, 4)
Juvenile Spondyloarthritis Disease Activity Index 
(JSpADA) (0-8)
3 (2, 3.5)
Patient/parent pain (VAS 0-10) 4 (2, 7)
Patient/parent disease activity (VAS 0-10) 4 (2, 6)
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 Legend. Patient characteristics at diagnosis. * Imaging results 
only available for 4 sties (N-152)  
 23
Table 3. Factors associated with first biologic prescription 
Legend. Results of multilevel mixed-effects logistic mode-
ling to determine factors associated with prescription of first 
biologic. 
Disease 
manifestation
Odds Ratio (95% 
CI) p-value
Hip arthritis 3.9 (1.7, 8.9) 0.001
Wrist arthritis 2.8 (1.4, 5.7) 0.003
Sacroiliitis 4 (1.5, 10.3) 0.005
Uveitis 2.1 (0.7, 5.9) 0.18
HLA-B27 positivity 1.25 (0.7, 2.3) 0.45
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Figure 1. Lowess plot to evaluate confounding by indication 
between prescription of a biologic and Juvenile Spondyloar-
thritis Disease Activity (JSpA DA). Disease activity scores up 
to and including the first prescription of a biologic were plotted 
against a binary variable defining if a patient was prescribed a 
biologic at that time point or not.  
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Table 4. Results of weighted GEE analysis for outcomes.  
Outcome (over time) Variable Estimate (95% CI) p-value
Active joint count Biologic 
DMARD 
Age 
Female Sex
-0.70 (-1.58, 0.18) 
-0.20 (-0.54, 0.15) 
0.06 (-0.02, 0.13) 
-0.81 (-1.33, -0.29)
0.12 
0.27 
0.13 
<0.01
Tender entheses count Biologic 
DMARD 
Age 
Female Sex 
HLA-B27 -
-0.04 (-0.53, 0.45) 
-0.27 (-0.49, -0.06) 
0.06 (0.01, 0.10) 
0.31 (0.02, 0.60) 
0.66 (0.39, 0.94)
0.87 
0.01 
<0.001 
0.03 
<0.01
Physician disease 
activity  (0,10)
Biologic 
DMARD 
Age 
Female Sex
-0.58 (-1.45, 0.30) 
-0.56 (-1.07, -0.06) 
0.04 (-0.02, 0.11) 
0.32 (-0.26, 0.89)
0.20 
0.03 
0.17 
0.28
JSpADA (0, 8) Biologic 
DMARD 
Age 
Female Sex
-0.89 (-1.94, 0.16) 
-0.15 (-0.74, 0.44) 
0.06 (0.06, 0.17) 
0.27 (-0.38, 0.92)
0.10 
0.62 
0.35 
0.41
JADAS-3 (0, 30) Biologic 
DMARD 
Age 
Female Sex
-2.30 (-4.28, -0.32) 
-0.68 (-0.56, 1.20) 
0.18 (-0.16, 0.53) 
3.20 (1.06, 5.34)
0.02 
0.48 
0.30 
<0.01
Patient-reported 
disease activity (0, 10)
Biologic 
DMARD 
Age 
Female Sex
-0.10 (-1.23, 1.04) 
-0.01 (-0.90, 0.88) 
0.07 (-0.11, 0.26) 
2.59 (1.39, 3.80)
0.87 
0.98 
0.45 
<0.01
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Legend. Results from repeated measures multivariate mo-
dels. Higher scores for physician disease activity, JSPA 
DAI, JADAS-3, patient-reported disease activity, and pa-
tient reported pain indicate poorer outcomes. 
Patient-reported pain (0, 
10)
Biologic 
DMARD 
Age 
Female Sex
-1.47 (-2.79, -0.16) 
-0.20 (-1.02, 0.62) 
0.09 (-0.12, 0.29) 
2.88 (1.68, 4.09)
0.03 
0.63 
0.41 
<0.01
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Figure 2. Patient disease manifestations and disease acti-
vity trajectories by treatment medication over the first 
year following initial diagnosis of enthesitis-related arth-
ritis modeled using marginal structural models. Trajecto-
ries during the first year following diagnosis of (A) active 
joint count, (B) JADAS-3, (C) tender enthesis count (strati-
fied by HLA-B27 status; gray=negative, black=positive), 
and (D) JSpA DAI for patients treated with neither biologic 
nor DMARD, DMARD monotherapy, biologic monothera-
py, and dual DMARD plus biologic therapy. 
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Figure 3. Patient disease manifestation and disease activity trajec-
tories by treatment medication over the first year following initial 
diagnosis of enthesitis-related arthritis modeled using marginal 
structural models. Trajectories during the first year following dia-
gnosis of (A) patient pain scores, (B) physician global disease activity 
scores, and (C) patient reported disease activity scores for those trea-
ted with neither biologic nor DMARD, DMARD monotherapy, biolo-
gic monotherapy, and dual DMARD plus biologic therapy. 
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Table 5. Features of poor prognosis and disease activity 
for active sacroiliac arthritis 
FEATURE OF POOR PROGNOSIS 
Radiographic damage of any joint (erosions or joint space 
narrowing by radiograph) 
DISEASE ACTIVITY LEVELS 
Low disease activity (must satisfy all) 
- normal back flexion 
- erythrocyte sedimentation rate or C-reactive protein level 
normal 
- physician global assessment of overall disease activity < 4 
of 10 
- patient/parent global assessment of overall well-being < 2 
of 10 
Moderate disease activity (does not satisfy criteria for low 
or high activity) 
- 1 or more features greater than low disease activity level 
AND fewer than 2 features of high disease activity 
High disease activity (must satisfy at least 2) 
- erythrocyte sedimentation rate or C-reactive protein level 
greater than twice upper limit of normal 
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- physician global assessment of overall disease activity ≥ 7 
of 10 
- patient/parent global assessment of overall well-being ≥ 4 
of 10 
from: 2011 American College of Rheumatology recommen-
dations for the treatment of juvenile idiopathic arthritis: ini-
tiation and safety monitoring of therapeutic agents for the 
treatment of arthritis and systemic features.  
Authors: Beukelman T, Patkar NM, Saag KG, Tolleson-Ri-
nehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, La-
xer RM; Lovell DJ, Martini A, Rabinovich CE, Rupert N. 
Arthritis Care Res. 2011;63(2):465-482. 
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